Treating Newly Diagnosed CD19+ Mixed Phenotype Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment for adults with a rare type of leukemia called mixed phenotype acute leukemia that has a specific marker (CD19). It aims to find out if this approach works and is safe for people who haven't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with mixed phenotype acute leukemia that tests positive for CD19.
- You cannot have had a certain type of chemotherapy called bevacizumab before.
- You cannot have had CAR-T cell therapy or other gene-modified cell treatments before.
- You must not have had other cancer treatments (like surgery, chemo, or targeted therapy) within a certain time before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—a Bcl-2 inhibitor (a type of protein blocker) and azacitidine (a chemotherapy drug)—to treat mixed phenotype acute leukemia (MPAL), a rare blood cancer. The goal is to see if this combination works better than standard treatments for people newly diagnosed with this disease.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new drug called BEBT-908 plus chemotherapy for people with acute lymphoblastic leukemia that has a specific genetic change (MEF2D) or a certain immune type (pre-B). It's for patients whose leukemia is in remission but still has detectable tiny amounts of disease (MRD positive).
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.